加替沙星治疗下呼吸道感染的临床疗效
摘要
加替沙星是近年来新研制的新一代氟喹诺酮类药物,其化学结构为8-甲氧基氟喹诺酮类外消旋化合物,具有抗菌谱广、抗菌活性强的特点。本实验应用加替沙星治疗下呼吸道感染患者,并以头孢吡肟作为对照,旨在评价其临床疗效与安全性。
出处
《黑龙江医药》
CAS
2008年第5期100-101,共2页
Heilongjiang Medicine journal
二级参考文献26
-
1赵树清,王金生.新型氟喹诺酮抗菌剂——AM—1155[J].中国医药情报,1996,2(4):249-252. 被引量:4
-
2Niederman MS,McCombs JS,Unger AN,et al.The cost of treating community-acquired pneumonia.Clin Ther,1998,20:820-837
-
3Niederman MS,Mandell LA,Anzueto A,et al.Guidelines for the management of adults with community-acquired pneumonia:diagnosis,assessment of severity,antimicrobial therapy,and prevention.Am J Respir Crit Care Med,2001,163:1730-1754
-
4Dunbar LM,Wunderink RG,Habib MP,et al.High-dose,short-course levofloxacin for community-acquired pneumonia:a new treatment paradigm.Clin Infect Dis,2003,7:752-760
-
5Finch R,Schurmann D,Collins O,et al.Randomized controlled trial of sequential intravenous (i.v.) and oral moxifloxacin compared with sequential i.v. and oral co-amoxiclav with or without clarithromycin in patients with community-acquired pneumonia requiring initial parenteral treatment.Antimicrob Agents Chemother,2002,46,1746-1754
-
6Faich GA,Morganroth J,Whitehouse AB,et al.Clinical experience with moxifloxacin in patients with respiratory tract infections.Ann Pharmacother,2004,38:749-754
-
7JLM. Oral and iv formulations of gatifoxacin cleared for US. market. Am J Health-Syst Pharm, 2000; 57:204
-
8Hosaka M, Kinoshita S, Toyama A, et al. Antibacterial properties of AM-1155, a new 8-methoxy quinolone. J Antimicrob Chemther,1995; 36:293
-
9Tomioka H, Saito H, Sato K. Comparative antimycobacterial activities of the newly synthesized quinolone AM-1155, sparfloxacin and ofloxacin. Antimicrob Agents Chemother, 1993;37:1259
-
10Takei M, Fukuda H, Yasue T, et al. Inhibitory activities of gatifloxacin (AM-1155), a newly developed fluoroquinolone, against bacterial and mammalian typeⅡ topoisomerase. Antimicro Agents Chemother, 1998;42:2678
共引文献89
-
1周蔚然,李柏完,杨扬.相同日剂量加替沙星单次与分2次治疗呼吸及泌尿系细菌感染临床疗效比较[J].中国医疗前沿,2008,3(6):106-108.
-
2王睿,裴斐,方翼,朱曼,王中孝,柴栋,王锡萍.中国健康志愿者单剂口服甲磺酸加替沙星片的药代动力学研究[J].中国药物应用与监测,2003(5):9-12.
-
3裴斐,王睿,方翼,朱曼,柴栋,王中孝.多剂口服甲磺酸加替沙星片药代动力学研究[J].中国药物应用与监测,2003(5):33-36.
-
4王晶,李永贵,刘葵葵,张锡霞.加替沙星眼用凝胶的制备及质量控制[J].生物医学工程研究,2011,30(4):257-259.
-
5赵丽,王卓,杨樟卫,傅翔,李珍,胡晋红.HPLC法同时测定输液中加替沙星和氨茶碱的含量及其应用[J].药学服务与研究,2004,4(2):160-162. 被引量:5
-
6王睿,裴斐,方翼,朱曼,王中孝,柴栋,王锡萍.中国健康志愿者单剂口服甲磺酸加替沙星片的药代动力学研究[J].中国抗生素杂志,2004,29(10):617-621. 被引量:4
-
7吴春萍,牟鸣,李和柏.2000—2003年我院抗感染药物应用分析[J].中国药业,2004,13(11):59-60. 被引量:14
-
8陈宜鸿,方翼,王国栋,王睿.加替沙星Ⅰ期临床试验中不良事件的研究[J].中华医院感染学杂志,2004,14(3):317-320. 被引量:12
-
9贾蓓,胡鹏,王文,肖永红,刘洪渝.加替沙星与左氧氟沙星注射液治疗急性淋菌性泌尿生殖道感染的对照研究[J].重庆医科大学学报,2004,29(6):798-799. 被引量:2
-
10顾海宁,蒋永祥,汪劲松.盐酸加替沙星的合成研究[J].浙江大学学报(理学版),2005,32(1):66-68. 被引量:5
-
1马培奇.甲氧基氟喹诺酮类抗菌药加替沙星和莫西沙星(下)[J].中国制药信息,2001,17(2):22-24.
-
2王洁妤,冯明.莫西沙星致老年患者精神症状的临床分析[J].中国医师进修杂志(内科版),2008,31(11):66-67. 被引量:5
-
3李江利,卫江英.加替沙星的不良反应及注意事项[J].中国医药指南,2009,7(3):54-56. 被引量:5
-
4罗庆红.加替沙星的临床应用及不良反应[J].现代中西医结合杂志,2007,16(22):3274-3275. 被引量:3
-
5何剑波,翁海霞,吴立琴,戴元荣.莫西沙星致严重低血糖1例[J].中华医院感染学杂志,2011,21(9):1891-1891. 被引量:7
-
6卢善亮,朱华,卢小兰,贾玲昌.加替沙星片剂与胶囊剂体外溶出度的比较[J].实用临床医药杂志,2005,9(7):84-85. 被引量:1
-
7凌凤娟.加替沙星致抽搐反应的预防及护理[J].中国实用护理杂志(下旬版),2006,22(6):14-14. 被引量:2
-
8陈鸣.加替沙星与血糖异常[J].中国药物滥用防治杂志,2008,14(2):122-124. 被引量:1
-
9卢素玉,张婉童.肾康注射液与莫西沙星注射液存在配伍禁忌[J].中国实用护理杂志,2013,29(31):35-35. 被引量:3
-
10李娟,江洪军,龚智华.加替沙星与炎琥宁存在配伍禁忌[J].现代保健(医学创新研究),2006(8).